High SLC2A1 expression correlates with poor prognosis in patients with surgically resected lung adenocarcinoma (LUAD), which suggests that SLC2A1 is a promising biomarker for LUAD (30). This evidence concerns the gene SLC2A1 and lung adenocarcinoma.